Jakarta – Concerns over the regulatory oversight of U.S.-made pharmaceuticals and medical devices entering Indonesia have been addressed by top government officials, who affirmed that existing standards for product safety and certification remain firmly in place. The clarification comes amid circulating reports suggesting potential exemptions for U.S. Products from Indonesian regulations, a claim officials have strongly refuted. The issue of obat-alkes AS yang masuk ke RI – or U.S. Drugs and medical devices entering Indonesia – has sparked public debate in recent days.
Secretary of the Cabinet, Teddy Indra Wijaya, stated unequivocally that there would be no loosening of regulations. “It is not true that U.S. Products will enter without supervision or be exempt from testing,” Wijaya said, as reported by the Cabinet Secretariat. He emphasized that all products circulating within Indonesia must adhere to existing certification requirements, including halal certification where applicable, and obtain the necessary import permits.
BPOM Authority Remains Intact
Reinforcing this message, Head of the National Agency of Drug and Food Control (BPOM), Taruna Ikrar, confirmed that BPOM retains full authority over the testing, licensing, supervision, and recall of products originating from the United States. “BPOM continues to carry out supervision before and after products circulate in the market,” Ikrar stated. “If proven problematic, products can be rejected for licensing or withdrawn from circulation.” This assurance aims to quell anxieties about a potential compromise in Indonesia’s regulatory safeguards.
The government’s response follows the circulation of a document titled ‘Agreement Between the United States of America and the Republic of Indonesia on Reciprocal Trade,’ specifically Annex III Article 2.5. This section reportedly stipulated that trade in U.S.-origin medical devices would not require adherence to BPOM standards. However, officials clarified that the agreement does not negate Indonesia’s national standards.
Details of the Trade Agreement
According to the circulated document, Indonesia would accept marketing authorization issued by the U.S. Food and Drug Administration (FDA) as sufficient proof that medical devices manufactured in the U.S. Meet Indonesian requirements for marketing approval. The agreement as well outlines the recognition of audit and certification of quality management systems for medical device manufacturers, aligning with the Medical Device Single Audit Program (MDSAP). It further suggests that Indonesia would not require periodic re-authorization for pharmaceutical products previously approved by the FDA, unless significant safety, efficacy, or quality concerns arise.
However, officials stress that this acceptance of FDA approvals does not equate to a complete waiver of Indonesian oversight. The agreement pertains specifically to low-risk medical devices where FDA approval is not even required, and it includes provisions for Indonesia to reject or recall products if issues are identified. The agreement also stipulates that products requiring halal certification must still obtain it, either from a halal certification body in the U.S. Or in Indonesia.
Halal Certification and Pharmaceutical Oversight
The insistence on halal certification for food and beverage products from the U.S. Underscores Indonesia’s commitment to its domestic regulations. “Products that are required to be certified must have a halal label, either from a halal body in the U.S. Or a halal body in Indonesia,” Wijaya explained. This requirement reflects the importance of halal standards for a significant portion of the Indonesian consumer market.
The government’s clarification also extends to pharmaceuticals. Products from the U.S. Still require FDA approval to be marketed domestically in Indonesia, and BPOM retains the authority to assess and approve these products based on their own safety and efficacy standards. MetroTVNews.com reported on the government’s denial of easing halal rules for U.S. Goods.
The situation highlights the complexities of international trade agreements and the importance of clear communication regarding regulatory frameworks. The Indonesian government’s swift response aims to reassure the public that national interests and consumer safety remain paramount.
Looking ahead, BPOM will continue to monitor imported products from the U.S. And enforce existing regulations. The agency is expected to provide further updates on its oversight activities in the coming weeks. Readers are encouraged to visit the BPOM website for the latest information on product safety and regulations.
If you have concerns about the safety or authenticity of a product, please report it to BPOM through their official channels.
